Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Reserpine is a small molecule alkaloid derived from the roots of Rauwolfia serpentina and Rauwolfia vomitoria. It acts as an adrenergic blocking agent primarily used for the treatment of mild to moderate hypertension and has also been used in psychiatric disorders such as schizophrenia and severe agitation. Its mechanism involves irreversible inhibition of the vesicular monoamine transporter 2 (VMAT2), which prevents norepinephrine and other monoamines (dopamine and serotonin) from being stored in synaptic vesicles. This leads to depletion of catecholamines from peripheral sympathetic nerve endings and central nervous system stores. The result is reduced sympathetic tone with lowered heart rate and blood pressure[1][2][4][5]. Due to its side effect profile—including risk of depression—its clinical use has declined but it remains a reference compound in research.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on reserpine.